Uses and limitations of electrophysiology studies for the selection of antiarrhythmic therapy

The Thebesian valve: Gatekeeper to the coronary sinus

Clinical cardiac procedures such as electrophysiology studies, catheter ablation of arrhythmias, retrograde cardioplegia delivery, cardiac resynchronization therapy and, more recently, percutaneous mitral annuloplasty, involve cannulation of the coronary sinus (CS). The presence of a membrane closing the orifice of the CS may cause difficulties during these interventions. Thus, detailed knowledge of the variations and anomalies of the valve of the CS, or the Thebesian valve, now has practical significance. To improve our understanding of this structure, classic anatomical dissection of 50 hearts from dissection room cadavers was performed. A Thebesian valve was present in the overwhelming majority (88%) of cases. Its morphology varied widely, from a few small strands of tissue, to a membrane covering more than half the CS ostium. A significant number (20%) of valves occluded >65% of the ostium, making them "potential complicating factors" in cannulation of the CS. An understanding of these anatomical variations may help in identifying and overcoming potential difficulties during clinical cardiac interventions.

Electropharmacologic effect of a standard dose of intravenous procainamide in patients with sustained ventricular tachycardia

BACKGROUND

Patients with inducible sustained ventricular tachycardia (VT) sometimes receive intravenous procainamide during electrophysiologic testing. Unfortunately, the responses to intravenous and subsequent oral drug therapy are variable and may be discordant.

HYPOTHESIS

It was the aim of this study to determine whether this variability might be explained by heterogeneity in the electropharmacologic response, even in a homogeneous population.

METHODS

We studied 42 patients who had spontaneous malignant ventricular arrhythmia and were inducible to sustained monomorphous VT during electrophysiologic testing. Each received 15 mg/kg of intravenous procainamide followed by a 2 mg/min infusion. Serum levels were drawn immediately following programmed stimulation. The mean procainamide level was 6.7 +/- 1.4 mcg/ml with an N-acetyl procainamide level of 1.0 +/- 0.5 mcg/ml. The 14 procainamide responders (5 of whom were noninducible and 9 whose VT cycle length increased > 100 ms) and the 28 nonresponders had similar procainamide and NAPA levels (6.5 +/- 1.4 vs. 6.7 +/- 1.4 mcg/ml).

RESULTS

There was no significant difference in baseline clinical parameters, His to ventricular electrogram (HV) interval, effective refractory period, or VT cycle length. Prolongation of the effective refractory period and infra His conduction time occurred to a similar extent in responders and nonresponders.

CONCLUSION

We conclude that procainamide has a consistent dose-response relationship with respect to refractoriness and conduction in patients with malignant arrhythmias. However, acute antiarrhythmic efficacy of procainamide cannot be predicted by clinical factors, drug levels, or drug-induced changes in common electrophysiologic parameters.

Syncope in elderly patients. Why their risk is higher

The elderly are at increased risk for syncope not only because of physiologic changes due to aging but also because they have a higher incidence of chronic illness and use a greater number of medications that may cause orthostatic hypotension. Although evaluation should emphasize cardiovascular and neurologic components, the cause may remain elusive in as many as 50% of patients.

Role of permanent pacemakers in the pharmacologic therapy of patients with reentrant tachyarrhythmias

Improved pacemaker technology has permitted application in more diverse groups of patients. A more recently described subset appears to be those with reentrant tachycardias treatable with antiarrhythmic drugs. Here, pacing offers the ability both to test the efficacy of a drug regimen and to provide adjunctive "fail-safe" therapy for those with episodic breakthrough. With the advent of more sophisticated devices, especially those with cardioversion/defibrillation capability, we anticipate a growing interest in these applications which will undoubtedly benefit patients.

Electrophysiology of beta blockers in supraventricular arrhythmias

beta-adrenergic blocking agents are efficacious in the treatment of patients with a variety of supraventricular tachycardias, based directly on their capacity to counter the effects of beta-adrenergic stimulation on sinus and atrioventricular nodal tissue. Specifically, beta blockers depress sinus node automaticity and inhibit atrioventricular nodal function by prolonging refractoriness and slowing conduction. Supraventricular arrhythmias that depend on these structures either for perpetuation or for conduction to the ventricles are predictably sensitive to beta blockade. These arrhythmias include sinus tachycardia, sinoatrial reentrant, atrioventricular nodal reentrant (dual pathway) and atrioventricular reciprocating (concealed bypass tract) tachycardias, as well as atrial flutter and fibrillation. beta blockers may also be used, in selected patients, to inhibit catecholamine-facilitated accessory pathway function by prolonging refractoriness. beta blockers offer particular clinical advantages, including an acceptable side-effect profile, titratable effect, varied pharmacology and reasonable concordance between efficacy of parenteral and oral dosage forms. The key element in the most effective use of these drugs appears to be an accurate arrhythmia diagnosis that allows for the most appropriate application of a reliable treatment form.

Risks and complications of clinical cardiac electrophysiologic studies: a prospective analysis of 1,000 consecutive patients

The complications of clinical cardiac electrophysiologic studies were prospectively evaluated in 1,000 consecutive patients studied in one laboratory with an unaltered protocol to better assess the risks of this procedure. There were 728 men and the mean age of the entire group was 58 years (range 16 to 84). Coronary artery disease was the most common type of heart disease (56%) and 200 patients had no identifiable organic heart disease. The indication for study was a ventricular tachyarrhythmia or cardiac arrest in 582 patients. Each patient underwent an initial (baseline) study and 444 patients underwent serial drug studies (2.7/patient). There was one death during these studies. Other major complications included arterial injury (0.4%), thrombophlebitis (0.6%), systemic arterial embolism (0.1%), pulmonary embolism (0.3%) and cardiac perforation (0.2%). Significant arrhythmic complications included catheter-induced permanent complete atrioventricular (AV) block in 1 patient, nonclinical atrial fibrillation that required therapy in 10 patients and severe proarrhythmic events in 12 (3%) of 397 patients undergoing drug studies for ventricular tachyarrhythmias. Cardioversion was required for termination of ventricular tachyarrhythmias in 179 baseline studies (53% of patients with inducible arrhythmia), and in an additional 35 patients, cardioversion was required at least once during follow-up studies. Although clinical cardiac electrophysiologic studies are associated with complications, the risks are small and acceptable.

Prognostic implications of complex ventricular ectopy in patients with and without structural heart disease. A study based on programmed electrical stimulation

Fifty-six patients with complex ventricular premature beats (Lown grade IVa, IVb), but no evidence of ventricular tachycardia on 48 hours of continuous monitoring were evaluated by programmed electrical stimulation. Thirty patients had coronary atherosclerotic heart disease, 3 had valvular heart disease, 2 had cardiomyopathy and 21 had no structural heart disease. Programmed stimulation identified two groups of subjects: Group I comprised 11 patients in whom ventricular tachycardia was induced and Group II comprised 45 patients (which included 21 patients without heart disease) in whom no ventricular tachycardia was induced. The incidence of left ventricular dysfunction (ejection fraction less than 40%) was significantly higher in Group I as compared to Group II (P less than 0.001). There was, however, no difference between the grade of ventricular ectopy, HV interval or the incidence of bundle branch block between the 2 groups. Patients with inducible ventricular tachycardia (Group I) were put on laboratory directed anti-arrhythmic drug therapy. Patients without inducible tachycardia (Group II) were not given anti-arrhythmic therapy. The patients were followed up for 34 +/- 10 months. The incidence of sudden death (36.3% vs 6.6%, P less than 0.001) was significantly higher in Group I as compared to Group II. No patients without structural heart disease died during the follow-up. Programmed electrical stimulation fails to induce ventricular tachycardia in patients with complex ventricular ectopy but no structural heart disease. It is, however, possible to define a high risk subset in patients with structural heart disease and complex ectopy. The high risk patients with inducible ventricular tachycardia do not seem to benefit by anti-arrhythmic drugs, which may independently increase the risk of sudden death in treated patients. Patients in whom ventricular tachycardia is not inducible have better left ventricular function, a good long-term prognosis and do not require anti-arrhythmic agents.